Drug Trial Radar · NCT01091168
Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Sep 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
594
Actual
Start
Jul 2009
Primary completion
Aug 27, 2012
Study completion Jan 2014
Sponsor
- Lead sponsor
- Pierre Fabre MedicamentIndustry
- Sponsor type
- Industry
- First posted
- Mar 23, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In metastatic breast cancer (MBC) patients who have already received anthracyclines, taxanes, antimetabolites and vinca-alkaloids and have developed drug resistance to these drugs, therapeutic options are very limited. Alkylating agents showed a modest activity in pretreated metastatic breast cancer. This phase III trial will compare the effectiveness and the safety profile of vinflunine to an alkylating agent of physician choice in MBC patients who have exhausted anthracyclines, taxanes, antimetabolites and vinca-alkaloids.
Conditions
- Breast Cancer
- Metastases
Interventions
vinflunineDrug
280 mg/m2 on day 1 of each cycle every 3 weeks
Alkylating agent of physician choice registered in cancerDrug
cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: From baseline up to 3 years 1 month
Locations
80 sites in 14 countries. Site status is shown where the registry gives one.
Site not named
Buenos Aires, Argentina
Site not named
Quilmes, Argentina
Site not named
Rosario, Argentina
Site not named
San Martin, Argentina
Site not named
San Miguel de Tucumán, Argentina
Site not named
Graz, Austria
Site not named
Salzburg, Austria
Site not named
Vienna, Austria
Site not named
Grodno, Belarus
Site not named
Homyel, Belarus
Site not named
Minsk, Belarus
Site not named
Vitebsk, Belarus
Site not named
Brussels, Belgium
Site not named
Haine-Saint-Paul, Belgium
Site not named
Yvoir, Belgium
Site not named
Angers, France
Site not named
Brest, France
Site not named
Clermont-Ferrand, France
Site not named
Dijon, France
Site not named
Grenoble, France
Site not named
Le Mans, France
Site not named
Lille, France
Site not named
Limoges, France
Site not named
Lorient, France
Site not named
Montpellier, France
Site not named
Nancy, France
Site not named
Nantes, France
Site not named
Nice, France
Site not named
Paris, France
Site not named
Pontoise, France
Site not named
Reims, France
Site not named
Rouen, France
Site not named
Saint-Brieuc, France
Site not named
Saint-Priest-en-Jarez, France
Site not named
Strasbourg, France
Site not named
Berlin, Germany
Site not named
Dortmund, Germany
Site not named
Essen, Germany
Site not named
Mainz, Germany
Site not named
Munich, Germany
Showing 40 of 80 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.